Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1460480
This article is part of the Research Topic The Tumor Microenvironment and Immunotherapy for Head and Neck Tumors View all 8 articles

The impact of dissociated response of immunotherapy on the treatment strategy of advanced head and neck cancer

Provisionally accepted
Siqing Jiang Siqing Jiang 1Xin Li Xin Li 2Jin Li Jin Li 1*
  • 1 Hunan Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, China
  • 2 Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China

The final, formatted version of the article will be published soon.

    Some special therapeutic responses may appear during immunotherapy, such as hyperprogression, pseudoprogression and so on. Dissociated response of immunotherapy has been clinically reported in recent years mainly in lung cancer and kidney cancer. Since there were poor prognosis and simple treatment of advanced head and neck cancer, the application of immunotherapy in head and neck cancer has risen in recent years.But the dissociated response of immunotherapy in head and neck cancer is rarely reported. We reported two series of cases of advanced head and neck cancer that showed dissociated response after immunotherapy, tumor progression was assessed by imaging methods such as PET-CT ， enhanced CT and enhanced MR, and reviewed the literature related to dissociated response in immunotherapy. We propose that the dissociated response of immunotherapy may affect the treatment strategy of advanced head and neck cancer, but more clinical analys es and researches are needed to confirm it.The dissociated response to immunotherapy may profoundly influence the decision -making of local and systemic therapy for advanced head and neck cancer with distant metastasis.

    Keywords: D issociated response, Immunotherapy, Advanced head and neck cancer, treatment strategy, Conversion therapy

    Received: 06 Jul 2024; Accepted: 17 Sep 2024.

    Copyright: © 2024 Jiang, Li and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jin Li, Hunan Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.